Document is current
Any future updates will be listed below
-
Authors
Serra, Riccardo
Smith, Stuart J.
Rowlinson, Jonathan
Gorelick, Noah
Moloney, Cara
McCrorie, Phoebe
Veal, Gareth J. https://orcid.org/0000-0002-1897-8678
Berry, Philip
Chalmers, Anthony J. https://orcid.org/0000-0002-1746-7278
Suk, Ian
Shakesheff, Kevin M.
Alexander, Cameron
Grundy, Richard G.
Brem, Henry
Tyler, Betty M.
Rahman, Ruman https://orcid.org/0000-0002-6541-9983
- License Information
-
More Information
Article History
Received: 21 May 2024
Revised: 1 October 2024
Accepted: 4 October 2024
First Online: 22 October 2024
Competing interests
: Dr Henry Brem is a paid consultant to Insightec and chairperson of the company’s Medical Advisory Board. Insightec is developing focused ultrasound treatments for brain tumors. This arrangement has been reviewed and approved by the Johns Hopkins University in accordance with its conflict-of-interest policies. Dr Brem receives research funding from NIH, Johns Hopkins University, Khatib Foundation, NICO Myriad Corporation, and philanthropy. He is a consultant for Accelerating Combination Therapies, Insightec, Candel Therapeutics, Inc., Catalio Nexus Fund II, LLC, LikeMinds, Inc*, Galen Robotics, Inc.* CraniUS*, and Nurami Medical*. Betty Tyler has research funding from NIH and is a co-owner for Accelerating Combination Therapies*. Ashvattha Therapeutics Inc. has also licensed one of her patents and she is a stockholder for Peabody Pharmaceuticals (*includes equity or options).
: All animals (live vertebrates) were treated in accordance with the policies and guidelines of the Johns Hopkins University (JHU) Animal Care and Use Program. Experimental protocols were Approved by the JHU Animal Care and Use Committee. All cages were illuminated by fluorescent lights set to a 12-hour light-dark cycle (7am-7pm), as per U.S. Public Health Service Policy on Humane Care and Use of Laboratory Animals guidelines.
